REG - Abingdon Health PLC - Abingdon Analytical Laboratory opens at Doncaster

Abingdon HealthAnnouncement

17/12/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241217:nRSQ3781Qa&default-theme=true

RNS Number : 3781Q  Abingdon Health PLC  17 December 2024

 

Abingdon Health plc

("Abingdon" or "the Company")

 

Abingdon Analytical Laboratory opens at Doncaster

 

York, U.K. 17 December 2024: Abingdon Health plc (AIM: ABDX), a leading
international medical device contract development and manufacturing
organisation (CDMO), announces the opening of its analytical laboratory at its
Doncaster facilities. The laboratory will be operated by the Company's
wholly-owned subsidiary, Abingdon Analytical Ltd.

 

The Group has been providing analytical laboratory services since 2023 as part
of its strategy to offer a comprehensive CDMO service that supports its
customers in bringing products to market. The services of an analytical
laboratory make a significant contribution to a product's regulatory technical
file, including product stability testing, specificity, sensitivity,
assessment of detection limits, interference, cross-reactivity testing, and
method comparisons. The technical file is a key requirement for regulatory
approval by FDA, EU IVDR, UKCA and other regulatory authorities. Abingdon
Analytical Ltd will provide its services for the lateral flow testing market
and for adjacent sectors, such as other immunodiagnostic products and
molecular diagnostics.

 

The Group is investing up to £1 million of the proceeds of the recent placing
(https://www.londonstockexchange.com/news-article/ABDX/result-of-placing/16586682)
to strengthen its analytical laboratory service, part of which has financed
this opening.

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "This
next step in our expansion provides a comprehensive analytical services
laboratory, forming a bridge between our CDMO and regulatory service
offerings, and linking our group companies, Abingdon Health, IVDeology and CS
(Life Sciences). The capability to generate analytical and product performance
data for use in a product's regulatory technical file adds another element to
the broad portfolio of services we offer our customers. The first major
contract announced today
(https://www.londonstockexchange.com/news-article/ABDX/contract-win-sexually-transmitted-disease-tests/16814507)
illustrates the benefit of adding this analytical capability to our CDMO
offering."

 

Enquiries

 

 Abingdon Health plc                                                             www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                            Via Walbrook PR
 Chris Hand, Executive Chairman

 Zeus (Sole Broker and Nominated Adviser)                                          Tel: +44 (0) 20 3829 5000
 Chris Fielding / Alexandra Campbell-Harris (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                              +44 (0)7867 984 082

 

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

 

About Abingdon Health plc

 

Abingdon Health Group is a leading Medtech contract service provider offering
its services to an international customer base.

 

The Company's CDMO division (https://www.abingdonhealth.com/services/) offers
lateral flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health's
CDMO division has the internal capabilities to take lateral flow projects, in
areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
(https://cslifesciences.com) and IVDeology (https://www.ivdeology.co.uk) ,
provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) e-commerce site offers consumers a range
of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGRUPUPCUMM